An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Dapagliflozin Extended Release Capsules in Healthy Volunteers
Latest Information Update: 11 Mar 2022
At a glance
- Drugs Dapagliflozin (Primary) ; Dapagliflozin
- Indications Cardiovascular disorders; Metabolic disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lyndra
Most Recent Events
- 04 Mar 2022 Status changed from recruiting to discontinued.
- 15 Oct 2021 Planned number of patients changed from 40 to 34.
- 25 Feb 2020 Planned number of patients changed from 8 to 40.